Abstract 5488
Background
In the course of tumor growth, the cells that are far from the blood vessel are exposed to hypoxic conditions. As part of this process transcription factors (TFs) of the Snail family (Snail, Slug, Twist1, and Zeb1) are activated launching the epithelial-mesenchymal transition (EMT) program. Snail family factors are the most studied as stimulators of EMT, promoting tumor progression, migration and invasion of tumor cells. The aim of our research is to study adaptive mechanisms of human breast cancer (BC) cells to hypoxia and the analysis of the role of the TF Snail in this process.
Methods
We used human BC cells MCF-7, MDA-MB-231 and HBL-100 which were cultured in standard DMEM containing 10% fetal calf serum at 37oC and 5% СО2. For hypoxia modeling, the cells were cultured in a CO2-incubator maintaining O2 concentration at 1%.
Results
Knockdown of the Snail by small interfering RNA (siRNA) leads to increased sensitivity of breast cancer cells to hypoxia, due to increased blocking of cells in the S-phase of cell cycle. Cells were more resistant to hypoxia at a lower density, where Snail expression was increased, but further hyperexpression of Snail had not lead to increased resistance to hypoxia. Knockdown of Snail leads to an compensatory increase of Slug`s expression, while the knockdown of Twist1 and Zeb1 leads to decreased Slug expression. Knockdown of Twist1 decreases cell proliferation both in hypoxia and normoxia, through activation of cell cycle inhibitor p21WAF1, specifically in the G2/M phase, in p53-wild type HBL-100 cells. We used a chemical inhibitor of p53-Snail interaction GN25, to examine if blocking of this interaction could lead to increased sensitivity in hypoxia. We have shown that this compound has a greater cytotoxic effect in normoxia than hypoxia, due to increased Snail activity.
Conclusions
Modulation of Snail-associated signaling pathways is a perspective target for increase of cancer cell tolerance to chronic hypoxia, and inhibition of metastatic process in breast cancer cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grant no. 14.W03.31.0020 between the Ministry of Science and Education of the Russian Federation and Institute of Gene Biology, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract